

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

MAILED

Office of Regulatory Policy HFD - 7 5600 Fishers Lane (Rockwall II Rm. 1101) Rockville, MD 20857

JAN 18 2007

CENTRAL REEXAMINATION UNIT

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 5,914,331. The application was filed on August 29, 2003, under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571)272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner

for Patent Examination Policy

cc: Mark Bosse

Intellectual Property Department

Gilead Sciences, Inc. 33 Lakeside Dr.

Foster City, CA 94404

RE: Emtriva® (emtricitabine) FDA Docket No. 05E-0259